US20030108613A1 - Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device - Google Patents

Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device Download PDF

Info

Publication number
US20030108613A1
US20030108613A1 US10/322,475 US32247502A US2003108613A1 US 20030108613 A1 US20030108613 A1 US 20030108613A1 US 32247502 A US32247502 A US 32247502A US 2003108613 A1 US2003108613 A1 US 2003108613A1
Authority
US
United States
Prior art keywords
separation space
magnetic
separation
gradient field
soft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/322,475
Inventor
Werner Weitschies
Thomas Rheinlander
Wolfgang Ebert
Bernard Better
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to US10/322,475 priority Critical patent/US20030108613A1/en
Publication of US20030108613A1 publication Critical patent/US20030108613A1/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCHERING AKTIENGESELLSCHAFT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D35/00—Filtering devices having features not specifically covered by groups B01D24/00 - B01D33/00, or for applications not specifically covered by groups B01D24/00 - B01D33/00; Auxiliary devices for filtration; Filter housing constructions
    • B01D35/06—Filters making use of electricity or magnetism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/02—Magnetic separation acting directly on the substance being separated
    • B03C1/035—Open gradient magnetic separators, i.e. separators in which the gap is unobstructed, characterised by the configuration of the gap
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/18—Magnetic separation whereby the particles are suspended in a liquid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/26—Details of magnetic or electrostatic separation for use in medical applications

Definitions

  • the invention relates to the object that is characterized in the claims, i.e., a device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, process for separating magnetic materials from pharmaceutical preparations, and agents that are produced with the aid of the device according to the invention and the process according to the invention.
  • foreign particles in the form of metallic particulate contaminants can result from production operations with metal tools or in metal containers or by injection instruments.
  • the pharmacopeia stipulate the maximum limits, weighted according to particle size, for the number of foreign particles for pharmaceutical preparations that are to be administered parenterally, here especially in the case of infusions.
  • These foreign particles are frequently ferromagnetic, ferrimagnetic, superparamagnetic or paramagnetic compounds.
  • Naturally occurring ferromagnetic contaminants of a starting substance can be separated according to a process that is described in U.S. Pat. No. 4,119,700.
  • the ferromagnetic contaminants are separated with the aid of a magnetic field.
  • Processes for magnetic separation of biological materials are known from laid-open specifications WO 90/07380 and WO 83/02405.
  • Laid-open specification WO 90/07380 describes a device in which a separation space is surrounded by a permanent magnet and which has an inlet and an outlet.
  • the object of this invention was therefore to develop a device that makes it possible to separate magnetic particles, such as, e.g., metal contaminants, quickly and simply from pharmaceutical preparations and to simplify the separation process to such an extent that it can be done by the user himself.
  • a device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, was developed that is characterized by the following feature: the device is designed in the form of an attachment filter for injection instruments or infusion instruments.
  • the device makes it possible to separate all compounds that are ferromagnetic, ferrimagnetic, superparamagnetic, or paramagnetic.
  • the gradient field that is used for separation has to be considerably stronger than the gradient of the natural field.
  • the selection of the suitable gradient field depends on the magnetic moment of the substance that is to be separated. To separate paramagnetic compounds from diamagnetic pharmaceutical preparations, high-gradient fields are necessary.
  • the respective pharmaceutical preparation or its starting or intermediate product is directed through the device and thus through a magnetic gradient field.
  • the higher the gradient of the magnetic gradient field the stronger the force that acts on the paramagnetic, ferrimagnetic, superparamagnetic, or ferromagnetic contaminants.
  • Pharmaceutical agents and pharmaceutical adjuvants are generally diamagnetic and therefore experience a force that is very low in comparison to the paramagnetic, ferrimagnetic, superparamagnetic, or ferromagnetic contaminants; moreover, said force does not cause them to travel in the direction of the gradient but rather repels them.
  • the separation of the undesirable magnetic particles is carried out with the aid of a flow process.
  • the flow rate has to be matched to the magnetic moments of the ferromagnetic, ferrimagnetic, or superparamagnetic substances that are to be separated and the field gradients that are applied.
  • the embodiment of the device according to the invention can be implemented in different ways.
  • the magnetic gradient field in the separation space can be generated by, for example, a permanent magnet or an electromagnet that is attached outside the separation space.
  • a permanent magnet or an electromagnet that is attached outside the separation space.
  • the separation space can consist of paramagnetic or soft-magnetic material and/or to contain paramagnetic or preferably soft-magnetic material.
  • the magnetic gradient field in the separation space can, however, also be generated by a permanent-magnetic material which forms the separation space or is found in a separation space.
  • the magnetic gradient field in the separation space can be generated by a conductor through which the current flows and which is located either in the separation space or surrounds the separation space.
  • the separation space it can again be very helpful for the separation space to consist of paramagnetic or soft-magnetic material and/or to contain paramagnetic or preferably soft-magnetic material.
  • Soft-magnetic substances are preferably soft-magnetic iron or steel, especially in the form of fine shot (e.g., balls a few millimeters in diameter) or frits or in the form of wire (such as, e.g., steel wool, nets, or sieves).
  • the walls of the separation space, as well as the soft-magnetic or paramagnetic materials and the conductors through which the current flows and that are found within the separation space can also be provided with suitable protective layers for protection against undesirable chemical reactions, such as, e.g., corrosion.
  • protective layers can be the materials that are known from materials science. Suitable are, for example, chromium platings, protective layers made of stable oxides (such as aluminum oxide), or plastic coatings (e.g., PVC, polystyrene, polyethylene).
  • plastic coatings e.g., PVC, polystyrene, polyethylene
  • FIG. 1 Examples of possible embodiments of the device according to the invention are shown in FIG. 1 as attachment filters.
  • the device according to the invention can also be integrated into injection or infusion instruments. Examples of devices that are integrated into infusion instruments for magnetic separation are depicted in FIGS. 2 and 3. Another embodiment of a device that is integrated into an injection instrument is depicted in FIG. 4.
  • the different embodiments that are outlined in FIG. 1, such as for example, the use of permanent-magnetic balls or conductors through which current flows, can be used for magnetic separation in all devices according to the invention that are integrated into infusion or injection instruments.
  • the rate of flow of the liquid that is to be separated and its retention time or the ratio of the liquid that is to be separated to the magnetized, wetted surface in the holes can be adjusted so that an optimum degree of separation is achieved.
  • the rate of flow in the steel disk or in the cylinder can be reduced if several steel disks or cylinders are used one behind the other for separation and the holes of the disks or cylinders are arranged offset to one another.
  • the device according to the invention for magnetic separation of pharmaceutical preparations it is especially advantageous that the latter can be sterilized with simple agents, such as, for example, by heat treatment, autoclaving with expanded water vapor, and gassing with ethylene oxide.
  • said device according to the invention is much more stable than conventional membrane or pore filters.
  • the device according to the invention can also be especially useful as a prefilter to reduce the numbers of particles before conventional filtration processes, such as, for example, sterile filtration.
  • Another aspect of the invention relates to the production of pharmaceutical agents, especially contrast media, which can be obtained with the aid of the device according to the invention.
  • the device according to the invention is suitable for selecting from pharmaceutical preparations certain particles that are based on paramagnetic, superparamagnetic, ferromagnetic, or ferrimagnetic particles.
  • the particles that have an especially high magnetic moment can be separated from a pharmaceutical formulation that contains a mixture of different magnetic particles (such as, e.g., a magnetite-containing suspension, as is used in magnetic resonance tomography).
  • a pharmaceutical formulation that contains a mixture of different magnetic particles (such as, e.g., a magnetite-containing suspension, as is used in magnetic resonance tomography).
  • Agents that contain magnetic particles are used as, for example, contrast media in nuclear spin tomography. There, i.a., suspensions based on superparamagnetic magnetites are used. Surprisingly enough, it is possible here to separate a particle mixture on the basis of, i.a., the gradient field intensity according to its magnetic moments, i.e., here the process according to the invention can be controlled in such a way that not complete deposition of the magnetic particles is accomplished, but rather selective separation, whereby especially the particles with high magnetic moments are retained.
  • agents that are obtained in this case have considerably better properties, surprisingly enough, than the original particle suspensions.
  • agents for special new applications such as, e.g., for use as contrast media in magnetic resonance angiography or magnetic resonance lymphography, are obtained.
  • influence can be exerted on the relaxation behavior of the resulting agents and thus on contrast enhancement in the MRT process.
  • a T 1 -relaxivity alteration in other cases the T 2 -relaxivity alteration (or a suitable combination of the two) of the hydrogen atoms of physiological molecules that are adjacent to the administered superparamagnetic particles is used to make a diagnosis or diagnostic picture.
  • influence can also be exerted on these parameters—as also shown in the examples below.
  • the device according to the invention is further used in separating particulate ferromagnetic or ferrimagnetic contaminants from paramagnetic pharmaceutical preparations, such as, for example, solutions of iron salts or colloidal iron dextran (e.g., iron dextran injection, USP XXV), which are used to treat iron-deficient anemias.
  • paramagnetic pharmaceutical preparations such as, for example, solutions of iron salts or colloidal iron dextran (e.g., iron dextran injection, USP XXV), which are used to treat iron-deficient anemias.
  • a magnetic filter as is sketched in FIG. 1 e, is built up from a ring magnet (RL 19, IBS Magnet Berlin, outside diameter 19 mm, inside diameter 6.5 mm, height 10 mm) and a separation space that is arranged in the inside volume of the ring magnet.
  • the separation space consists of a wall made of plastic and is filled with steel wool.
  • a magnetic filter as is sketched in FIG. 1 a, is built up from a ring magnet (NE 1556, IBS Magnet Berlin, outside diameter 15 mm, inside diameter 5 mm, height 6 mm) and a separation space that is arranged in the inside volume of the ring magnet.
  • the separation space consists of a plastic wall and is filled with iron shot balls (diameter of about 0.3 mm).
  • iron shot balls diameter of about 0.3 mm.
  • 0.8 ml of a superparamagnetic colloidal solution of iron oxide nanoparticles produced according to U.S. Pat. No.
  • Example 7 with an iron content of 500 mmol/l and a T 2 -relaxivity (r 2 ) of about 160 l/(mmol s) is filtered through the magnetic filters under the action of hydrostatic pressure.
  • the T 2 -relaxivity (r 2 ) of the filtrate is about 60 l/(mmol s).
  • FIG. 6 shows the MR angiogram of the “unfiltered” magnetite suspension. The contrast effect that is achieved after 1 minute or 15 minutes is of little diagnostic informational value.
  • FIG. 7 shows the MR angiogram of the “filtered” magnetite suspension [(a) precontrast, (b) 1 min p.i.), (c) 30 minutes p.i.].
  • the contrast medium preparation that is prepared according to the invention is extremely well suited for magnetic resonance angiography compared to the untreated substance.
  • a magnetic filter as is sketched in FIG. 1 a, is built up from a ring magnet (NE 2016, IBS Magnet Berlin, outside diameter 20 mm, inside diameter 10 mm, height 6 mm) and a separation space that is arranged in the inside volume of the ring magnet.
  • the separation space consists of a wall made of plastic and is filled with iron shot balls (diameter about 0.3 mm).
  • iron shot balls diameter about 0.3 mm.
  • 0.8 ml of a superparamagnetic colloidal solution of iron oxide nanoparticles produced in U.S. Pat. No.
  • Example 7 4,101,435; Example 7) with an iron content of 500 mmol/l and a T 2 -relaxivity (r 2 ) of about 160 l/(mmol s) is filtered through the magnetic filters under the action of hydrostatic pressure.
  • FIG. 8 The angiograms that are obtained with this preparation are shown in FIG. 8, whereby even after one minute, a differentiation of the vessels can be detected, as is achieved only at a considerably later time in the case of the preparation that is produced according to Example 2.

Abstract

The invention relates to a device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, whereby the device is embodied in the form of an attachment filter for injection instruments or infusion instruments.

Description

  • The invention relates to the object that is characterized in the claims, i.e., a device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, process for separating magnetic materials from pharmaceutical preparations, and agents that are produced with the aid of the device according to the invention and the process according to the invention. [0001]
  • In pharmaceutical preparations, foreign particles in the form of metallic particulate contaminants can result from production operations with metal tools or in metal containers or by injection instruments. For the protection of patients, therefore, the pharmacopeia stipulate the maximum limits, weighted according to particle size, for the number of foreign particles for pharmaceutical preparations that are to be administered parenterally, here especially in the case of infusions. These foreign particles are frequently ferromagnetic, ferrimagnetic, superparamagnetic or paramagnetic compounds. [0002]
  • Naturally occurring ferromagnetic contaminants of a starting substance can be separated according to a process that is described in U.S. Pat. No. 4,119,700. Here, the ferromagnetic contaminants are separated with the aid of a magnetic field. Processes for magnetic separation of biological materials are known from laid-open specifications WO 90/07380 and WO 83/02405. Laid-open specification WO 90/07380 describes a device in which a separation space is surrounded by a permanent magnet and which has an inlet and an outlet. [0003]
  • In the case of pharmaceutical preparations, the number of foreign particles to date is reduced if at all possible by processes of adsorption filtration or membrane filtration. Especially in the case of contaminants that are produced by user actions, such as, e.g., spraying pharmaceutical agents into infusion containers, however, it is difficult to reduce the number of foreign particles since correspondingly small-pore membrane filters often can be operated only with additional mechanical pressure. In most cases, filter inserts in infusion instruments therefore have pore sizes of several micrometers, which, however, lead to unsatisfactory retention rates for foreign particles. In the case of particulate pharmaceutical preparations, such as, e.g., parenteral fat emulsions or crystal suspensions as depot dosage forms, separating foreign particles by membrane or adsorption filtration is generally not possible at all. [0004]
  • The object of this invention was therefore to develop a device that makes it possible to separate magnetic particles, such as, e.g., metal contaminants, quickly and simply from pharmaceutical preparations and to simplify the separation process to such an extent that it can be done by the user himself. [0005]
  • This object is achieved by this invention. [0006]
  • A device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, was developed that is characterized by the following feature: the device is designed in the form of an attachment filter for injection instruments or infusion instruments. [0007]
  • The device makes it possible to separate all compounds that are ferromagnetic, ferrimagnetic, superparamagnetic, or paramagnetic. [0008]
  • The gradient field that is used for separation has to be considerably stronger than the gradient of the natural field. The selection of the suitable gradient field depends on the magnetic moment of the substance that is to be separated. To separate paramagnetic compounds from diamagnetic pharmaceutical preparations, high-gradient fields are necessary. [0009]
  • To separate the undesirable magnetic compounds, the respective pharmaceutical preparation or its starting or intermediate product is directed through the device and thus through a magnetic gradient field. The higher the gradient of the magnetic gradient field, the stronger the force that acts on the paramagnetic, ferrimagnetic, superparamagnetic, or ferromagnetic contaminants. Pharmaceutical agents and pharmaceutical adjuvants (such as, for example, water) are generally diamagnetic and therefore experience a force that is very low in comparison to the paramagnetic, ferrimagnetic, superparamagnetic, or ferromagnetic contaminants; moreover, said force does not cause them to travel in the direction of the gradient but rather repels them. To separate magnetic contaminants from diamagnetic preparations, therefore, in contrast to filtration through small-pore filters (e.g., 0.22 μm membrane filter), no special pressure generally needs to be exerted in the separation according to the invention in the magnetic gradient field; generally the force of gravity or hydrostatic pressure is sufficient. [0010]
  • With the device according to the invention, the separation of the undesirable magnetic particles is carried out with the aid of a flow process. In the case of flow processes, in contrast to static processes, the flow rate has to be matched to the magnetic moments of the ferromagnetic, ferrimagnetic, or superparamagnetic substances that are to be separated and the field gradients that are applied. [0011]
  • The embodiment of the device according to the invention can be implemented in different ways. The magnetic gradient field in the separation space can be generated by, for example, a permanent magnet or an electromagnet that is attached outside the separation space. To increase the locally effective gradient of the magnetic field, it can be very helpful in this case for the separation space to consist of paramagnetic or soft-magnetic material and/or to contain paramagnetic or preferably soft-magnetic material. [0012]
  • The magnetic gradient field in the separation space can, however, also be generated by a permanent-magnetic material which forms the separation space or is found in a separation space. [0013]
  • In addition, the magnetic gradient field in the separation space can be generated by a conductor through which the current flows and which is located either in the separation space or surrounds the separation space. In both the above-mentioned cases, it can again be very helpful for the separation space to consist of paramagnetic or soft-magnetic material and/or to contain paramagnetic or preferably soft-magnetic material. [0014]
  • Soft-magnetic substances are preferably soft-magnetic iron or steel, especially in the form of fine shot (e.g., balls a few millimeters in diameter) or frits or in the form of wire (such as, e.g., steel wool, nets, or sieves). [0015]
  • The walls of the separation space, as well as the soft-magnetic or paramagnetic materials and the conductors through which the current flows and that are found within the separation space can also be provided with suitable protective layers for protection against undesirable chemical reactions, such as, e.g., corrosion. Such protective layers can be the materials that are known from materials science. Suitable are, for example, chromium platings, protective layers made of stable oxides (such as aluminum oxide), or plastic coatings (e.g., PVC, polystyrene, polyethylene). When conductors through which current flows are used inside the separation chamber to generate the magnetic gradient fields, insulation with known insulating materials (such as, e.g., plastics in the form of paint coatings) is necessary in any case. [0016]
  • Examples of possible embodiments of the device according to the invention are shown in FIG. 1 as attachment filters. The device according to the invention can also be integrated into injection or infusion instruments. Examples of devices that are integrated into infusion instruments for magnetic separation are depicted in FIGS. 2 and 3. Another embodiment of a device that is integrated into an injection instrument is depicted in FIG. 4. The different embodiments that are outlined in FIG. 1, such as for example, the use of permanent-magnetic balls or conductors through which current flows, can be used for magnetic separation in all devices according to the invention that are integrated into infusion or injection instruments. [0017]
  • By the diameter of the steel disks, the number and length of the holes, which correspond to the heights of the disks or the cylinders, the rate of flow of the liquid that is to be separated and its retention time or the ratio of the liquid that is to be separated to the magnetized, wetted surface in the holes can be adjusted so that an optimum degree of separation is achieved. In addition, the rate of flow in the steel disk or in the cylinder can be reduced if several steel disks or cylinders are used one behind the other for separation and the holes of the disks or cylinders are arranged offset to one another. [0018]
  • Another special embodiment is obtained if the steel disks in the upper part of the separation space cannot be magnetized or consist of non-magnetized material and the disks in the lower part of the separation space are magnetized by the outer ring magnets or by a coil through which current flows. This is achieved in that magnetic particles are retained exclusively in the lower part of the separation space. [0019]
  • In the device according to the invention for magnetic separation of pharmaceutical preparations, it is especially advantageous that the latter can be sterilized with simple agents, such as, for example, by heat treatment, autoclaving with expanded water vapor, and gassing with ethylene oxide. In addition, said device according to the invention is much more stable than conventional membrane or pore filters. The device according to the invention can also be especially useful as a prefilter to reduce the numbers of particles before conventional filtration processes, such as, for example, sterile filtration. [0020]
  • Another aspect of the invention relates to the production of pharmaceutical agents, especially contrast media, which can be obtained with the aid of the device according to the invention. The device according to the invention is suitable for selecting from pharmaceutical preparations certain particles that are based on paramagnetic, superparamagnetic, ferromagnetic, or ferrimagnetic particles. [0021]
  • This can be done by varying the field intensity. Thus, the particles that have an especially high magnetic moment can be separated from a pharmaceutical formulation that contains a mixture of different magnetic particles (such as, e.g., a magnetite-containing suspension, as is used in magnetic resonance tomography). [0022]
  • Agents that contain magnetic particles are used as, for example, contrast media in nuclear spin tomography. There, i.a., suspensions based on superparamagnetic magnetites are used. Surprisingly enough, it is possible here to separate a particle mixture on the basis of, i.a., the gradient field intensity according to its magnetic moments, i.e., here the process according to the invention can be controlled in such a way that not complete deposition of the magnetic particles is accomplished, but rather selective separation, whereby especially the particles with high magnetic moments are retained. [0023]
  • For their purpose in diagnosis, the agents that are obtained in this case have considerably better properties, surprisingly enough, than the original particle suspensions. Thus, agents for special new applications, such as, e.g., for use as contrast media in magnetic resonance angiography or magnetic resonance lymphography, are obtained. [0024]
  • Thus, with the aid of the device according to the invention, influence can be exerted on the relaxation behavior of the resulting agents and thus on contrast enhancement in the MRT process. For specific medical diagnostic devices or diagnostic problems, preferably a T[0025] 1-relaxivity alteration, in other cases the T2-relaxivity alteration (or a suitable combination of the two) of the hydrogen atoms of physiological molecules that are adjacent to the administered superparamagnetic particles is used to make a diagnosis or diagnostic picture. Via the magnetic separation, influence can also be exerted on these parameters—as also shown in the examples below.
  • With the aid of this device, the production of a pharmaceutical agent with altered magnetic properties from an existing pharmaceutical agent is thus possible. Since the uptake of particles introduced parenterally into humans or animals in the reticuloendothelial system (RES) depends on, i.a., their size, magnetic separation also makes it possible to exert influence on the in-vivo pharmacokinetics properties of pharmaceutical preparations. The methods known to date for controlling size distribution are unsatisfactory. The latter methods are based on expensive precipitation methods that are difficult to control in the production of pharmaceutical agent substances or on filtration, processes. The latter are, as already stated, associated with immanent drawbacks. [0026]
  • Separation of undesirable, comparatively larger superparamagnetic particles from colloidal pharmaceutical agent preparations by centrifuging or sedimentation processes is also extremely expensive with regard to materials processing or is unsuitable for other reasons, such as, e.g., inadequate stability of the pharmaceutical agent or its formulation. [0027]
  • The device according to the invention is further used in separating particulate ferromagnetic or ferrimagnetic contaminants from paramagnetic pharmaceutical preparations, such as, for example, solutions of iron salts or colloidal iron dextran (e.g., iron dextran injection, USP XXV), which are used to treat iron-deficient anemias. [0028]
  • The examples below are used for a more detailed explanation of the object of the invention, without intending that it be limited to these examples. [0029]
    • EXAMPLE 1
  • About 100 mg of iron filings is suspended in 10 ml of an aqueous solution of 4.69 g of gadopentetic acid, dimeglumine salt. A magnetic filter, as is sketched in FIG. 1[0030] e, is built up from a ring magnet (RL 19, IBS Magnet Berlin, outside diameter 19 mm, inside diameter 6.5 mm, height 10 mm) and a separation space that is arranged in the inside volume of the ring magnet. The separation space consists of a wall made of plastic and is filled with steel wool. The suspension is flowed through the magnetic filter by hydrostatic pressure without any other force acting on it. After magnetic filtration, microscopic study can show that the iron filings are separated from the contrast medium solution by the filter.
    • EXAMPLE 2
  • A magnetic filter, as is sketched in FIG. 1[0031] a, is built up from a ring magnet (NE 1556, IBS Magnet Berlin, outside diameter 15 mm, inside diameter 5 mm, height 6 mm) and a separation space that is arranged in the inside volume of the ring magnet. The separation space consists of a plastic wall and is filled with iron shot balls (diameter of about 0.3 mm). 0.8 ml of a superparamagnetic colloidal solution of iron oxide nanoparticles (produced according to U.S. Pat. No. 4,101,435; Example 7) with an iron content of 500 mmol/l and a T2-relaxivity (r2) of about 160 l/(mmol s) is filtered through the magnetic filters under the action of hydrostatic pressure. The T2-relaxivity (r2) of the filtrate is about 60 l/(mmol s).
  • As a ratio of relaxivities r[0032] 2/r1, a value of 7.4 was determined for the untreated solution, while a value of 3.2 was measured for the filtrate.
  • All MR angiograms (FIGS. [0033] 6-8) were recorded on an experimental MRT (SISCO SIS 85, 2.0 Tesla) using A 3 D FLASH technology (10/2, 6/40°).
  • As test animals, anesthetized (Rompun[0034] (R)/Ketavet(R), mixture 1:1) rats (Han. Wistar; ˜200 g of body weight) were used.
  • Both with the “unfiltered” starting substance and with the preparation that is “filtered” according to the invention, first in each case a precontrast picture was prepared, as well as pictures taken 1, 15, or 30 minutes after intravenous administration of the respective contrast medium. In this case, a dose of about 100 μmol of iron/kg of body weight was always used. [0035]
  • FIG. 6 shows the MR angiogram of the “unfiltered” magnetite suspension. The contrast effect that is achieved after 1 minute or 15 minutes is of little diagnostic informational value. [0036]
  • FIG. 7 shows the MR angiogram of the “filtered” magnetite suspension [(a) precontrast, (b) 1 min p.i.), (c) 30 minutes p.i.]. Here, even after one minute, a large number of vessels can be clearly detected; the effect increases dramatically 30 minutes after administration of the contrast medium. The contrast medium preparation that is prepared according to the invention is extremely well suited for magnetic resonance angiography compared to the untreated substance. [0037]
    • EXAMPLE 3
  • A magnetic filter, as is sketched in FIG. 1[0038] a, is built up from a ring magnet (NE 2016, IBS Magnet Berlin, outside diameter 20 mm, inside diameter 10 mm, height 6 mm) and a separation space that is arranged in the inside volume of the ring magnet. The separation space consists of a wall made of plastic and is filled with iron shot balls (diameter about 0.3 mm). 0.8 ml of a superparamagnetic colloidal solution of iron oxide nanoparticles (produced in U.S. Pat. No. 4,101,435; Example 7) with an iron content of 500 mmol/l and a T2 -relaxivity (r2) of about 160 l/(mmol s) is filtered through the magnetic filters under the action of hydrostatic pressure. The ratio of relaxivities r2 and r1 is, with the filtrate, r2/r1=2.1.
  • The angiograms that are obtained with this preparation are shown in FIG. 8, whereby even after one minute, a differentiation of the vessels can be detected, as is achieved only at a considerably later time in the case of the preparation that is produced according to Example 2. [0039]

Claims (28)

1. Device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, is characterized by the following feature:
the device is embodied in the form of an attachment filter for injection instruments or infusion instruments.
2. Device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, wherein
the device is integrated into injection or infusion instruments.
3. Device according to one of claims 1 or 2, wherein
the magnetic gradient field in the separation space is generated by a permanent magnet or an electromagnet that is attached outside the separation space.
4. Device according to one of claims 1 to 3, wherein
the separation space consists of paramagnetic or soft-magnetic material and/or contains paramagnetic or soft-magnetic material.
5. Device according to one of claims 1 or 2, wherein
the gradient field in the separation space is generated by permanent-magnetic material, which forms the separation space or is found in the separation space.
6. Device according to one of claims 1 or 2, wherein
the magnetic gradient field in the separation space is generated by a conductor through which current flows and which is either found in the separation space or surrounds the separation space.
7. Device according to one of claims 5 or 6, wherein
the separation space contains additional paramagnetic or soft-magnetic material.
8. Device according to one of claims 1 to 7, wherein
the device is sterile.
9. Device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space in which a magnetic gradient field prevails, and which has an inlet and an outlet, wherein
the separation space contains one or more soft-magnetic disks that are to be magnetized during separation, which are provided with holes through which the liquid that is to be separated is directed.
10. Device according to claim 9, wherein
several disks, whose holes are arranged offset to one another, are located one behind the other in the separation space.
11. Device according to claim 9 or 10, wherein
the disks in the upper part of the separation space cannot be magnetized or consist of non-magnetizable material, and the disks in the lower part of the separation space are magnetized by an outer ring magnet or a coil through which current flows.
12. Device according to one of claims 9 to 11, wherein
the soft-magnetic disks are made from high-grade steel.
13. Process for selective or complete separation of magnetic compounds from pharmaceutical preparations or their starting or intermediate products, wherein
the pharmaceutical preparation flows through a device that contains a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, and which is embodied in the form of an attachment filter for injection instruments and infusion instruments.
14. Process for selective or complete separation of magnetic compounds from pharmaceutical preparations or their starting or intermediate products, wherein
the pharmaceutical preparation flows through a device that is integrated into injection instruments or infusion instruments.
15. Process according to claim 13 or 14, wherein
the magnetic gradient field in the separation space is generated by a permanent magnet or an electromagnet that is attached outside the separation space.
16. Process according to claim 13, 14 or 15, wherein
the separation space consists of paramagnetic or soft-magnetic material and/or contains paramagnetic or soft-magnetic material.
17. Process according to claim 13 or 14, wherein
the gradient field is generated in the separation space by permanent-magnetic material, which forms the separation space or is found in the separation space.
18. Process according to claim 13 or 14, wherein
the magnetic gradient field is generated in the separation space by a conductor through which current flows and which either is found in the separation space or surrounds the separation space.
19. Process according to one of claims 17 or 18, wherein
the separation space additionally contains paramagnetic or soft-magnetic material.
20. Process according to one of claims 13 to 19, wherein
the device is sterile.
21. Process for selective or complete separation of magnetic compounds from pharmaceutical preparations or their starting or intermediate products, wherein
the pharmaceutical preparation flows through a device that contains a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, and which in addition contains one or more soft-magnetic disks that are to be magnetized during separation, which are provided with holes through which the pharmaceutical preparation is directed.
22. Process according to claim 21, wherein
several disks, whose holes are arranged offset to one another, are located one behind the other in the separation space.
23. Process according to claim 21 or 22, wherein
the disks in the upper part of the separation space cannot be magnetized or consist of non-magnetizable material, and the disks in the lower part of the separation space are magnetized by an outer ring magnet or a coil through which current flows.
24. Process according to one of claims 21 to 23, wherein
the soft-magnetic disks are made of high-grade steel.
25. Contrast media for magnetic resonance tomography, that can be obtained by a pharmaceutical preparation based on paramagnetic, superparamagnetic, ferromagnetic, or ferrimagnetic particles being directed through the device according to one of claims 1 to 12.
26. Contrast media for magnetic resonance angiography and/or magnetic resonance lymphography, that can be obtained by a pharmaceutical preparation based on paramagnetic, superparamagnetic, ferromagnetic, or ferrimagnetic particles being directed though a device according to one of claims 1 to 12.
27. Pharmaceutical preparation, from which all foreign particles are removed with the aid of a device according to one of claims 1 to 8.
28. Contrast media, from which metal foreign particles are removed with the aid of a device according to one of claims 1 to 8.
US10/322,475 1996-08-05 2002-12-19 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device Abandoned US20030108613A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/322,475 US20030108613A1 (en) 1996-08-05 2002-12-19 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19632416 1996-08-05
DE19632416.5 1996-08-05
US08/904,765 US6517813B1 (en) 1996-08-05 1997-08-01 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device
US10/322,475 US20030108613A1 (en) 1996-08-05 2002-12-19 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/904,765 Division US6517813B1 (en) 1996-08-05 1997-08-01 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Publications (1)

Publication Number Publication Date
US20030108613A1 true US20030108613A1 (en) 2003-06-12

Family

ID=7802388

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/904,765 Expired - Fee Related US6517813B1 (en) 1996-08-05 1997-08-01 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device
US10/322,475 Abandoned US20030108613A1 (en) 1996-08-05 2002-12-19 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/904,765 Expired - Fee Related US6517813B1 (en) 1996-08-05 1997-08-01 Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Country Status (19)

Country Link
US (2) US6517813B1 (en)
EP (1) EP0915738B1 (en)
JP (1) JP2000516131A (en)
KR (1) KR100502881B1 (en)
CN (1) CN1151846C (en)
AR (1) AR008817A1 (en)
AT (1) ATE211950T1 (en)
AU (1) AU727764B2 (en)
CA (1) CA2262685C (en)
DE (2) DE29713847U1 (en)
DK (1) DK0915738T3 (en)
ES (1) ES2171985T3 (en)
HU (1) HUP0001608A3 (en)
IL (1) IL128057A (en)
NO (1) NO318377B1 (en)
NZ (1) NZ333962A (en)
PT (1) PT915738E (en)
WO (1) WO1998005430A1 (en)
ZA (1) ZA976967B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026823A1 (en) * 2004-09-09 2006-03-16 Bell, Glenda, Fay Separation of plastic and elastomers for food and pharmaceutical products
US20090299172A1 (en) * 2006-06-06 2009-12-03 Guerbet Water Diffusion imaging and Uspio
CN102178986A (en) * 2011-04-13 2011-09-14 李明 Blood extracorporeal circulation magnetic sterilizing device

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0915738T3 (en) * 1996-08-05 2002-05-06 Schering Ag Method for preparing contrast agents for magnetic resonance imaging
DE19938372A1 (en) * 1999-08-09 2001-03-08 Diagnostikforschung Inst Method and device for separating magnetic particles
DE10010638A1 (en) 2000-03-03 2001-09-13 Osram Opto Semiconductors Gmbh Making light emitting semiconducting body with luminescence conversion element involves applying suspension with solvent, adhesive, luminescent material
DE10046514A1 (en) 2000-09-15 2002-04-25 Diagnostikforschung Inst Process for imaging and diagnosis of thrombi using magnetic resonance imaging using particulate contrast media
DE10137515A1 (en) * 2001-07-26 2003-02-13 Diagnostikforschung Inst Production of pharmaceutical preparations in charged particle dispersion form, e.g. contrast agent dispersion, including separation of particles using ion exchangers or by electrophoresis
WO2006107288A2 (en) * 2004-02-17 2006-10-12 E.I.Dupont De Nemours And Company Magnetic field enhanced cake-filtration solid-liquid separations
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
US8066877B2 (en) * 2005-02-17 2011-11-29 E. I. Du Pont De Nemours And Company Apparatus for magnetic field and magnetic gradient enhanced filtration
EP1738773A1 (en) * 2005-06-29 2007-01-03 Schering AG Composition comprising magnetic iron oxide particles and use thereof in medical imaging
EP1738774A1 (en) * 2005-06-29 2007-01-03 Schering AG Compositions comprising magnetic iron oxide particles and use thereof in medical imaging
CN103006589B (en) * 2011-09-27 2015-11-25 闫亚梅 Amoxicillin dispersible tablet and production method thereof
CN106975567B (en) * 2017-05-17 2018-10-09 谢齐容 Iron impurities removal device and its method in medicinal material
CN108287236B (en) * 2017-11-24 2020-03-13 中国农业大学 Fluorescence biosensor based on high-gradient magnetic separation and quantum dots and application thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817389A (en) * 1973-01-15 1974-06-18 Sherwood Medical Ind Inc Filter device in tubular fitting for medical injection equipment and the like
US4101435A (en) * 1975-06-19 1978-07-18 Meito Sangyo Kabushiki Kaisha Magnetic iron oxide-dextran complex and process for its production
US4707255A (en) * 1986-07-29 1987-11-17 Olaf Fjeldsend A/S Apparatus for magnetic treatment of flowing liquid
US4863715A (en) * 1984-03-29 1989-09-05 Nycomed As Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material
US5045304A (en) * 1988-08-31 1991-09-03 Wayne State University Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same
US5160726A (en) * 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
US5268165A (en) * 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
US5328681A (en) * 1991-01-19 1994-07-12 Meito Sangyo Kabushiki Kaisha Composition comprising magnetic metal oxide ultrafine particles and derivatized polysaccharides
US5411863A (en) * 1988-12-28 1995-05-02 S. Miltenyi Methods and materials for improved high gradient magnetic separation of biological materials
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US5424419A (en) * 1991-06-11 1995-06-13 Meito Sangyo Kabushiki Kaisha Oxidized complex comprising water-soluble carboxypolysaccharide and magnetic iron oxide
US5766572A (en) * 1992-08-05 1998-06-16 Meito Sangyo Kabushiki Kaisha Water-soluble carboxypolysaccharide-magnetic iron oxide complex having a small particle diameter
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
US5916539A (en) * 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
US6048515A (en) * 1994-08-04 2000-04-11 Institut Fur Diagnostikforschung Gmbh Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US6207134B1 (en) * 1994-09-27 2001-03-27 Nycomed Imaging As Ultrafine lightly coated superparamagnetic particles for MRI
US6517813B1 (en) * 1996-08-05 2003-02-11 Schering Ag Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60241914A (en) * 1984-05-16 1985-11-30 Hitachi Plant Eng & Constr Co Ltd Corrosion-resistant filter medium for electromagnetic filter
US4641517A (en) 1984-12-20 1987-02-10 United Technologies Corporation Control system actuator position synthesis for failure detection
JPS6211519A (en) * 1985-07-05 1987-01-20 Agency Of Ind Science & Technol Sorting element for magnetic separator
US5055288A (en) 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
DE4309333A1 (en) * 1993-03-17 1994-09-22 Silica Gel Gmbh Superparamagnetic particles, process for their production and use thereof
US5514340A (en) * 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817389A (en) * 1973-01-15 1974-06-18 Sherwood Medical Ind Inc Filter device in tubular fitting for medical injection equipment and the like
US4101435A (en) * 1975-06-19 1978-07-18 Meito Sangyo Kabushiki Kaisha Magnetic iron oxide-dextran complex and process for its production
US4863715A (en) * 1984-03-29 1989-09-05 Nycomed As Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material
US4707255A (en) * 1986-07-29 1987-11-17 Olaf Fjeldsend A/S Apparatus for magnetic treatment of flowing liquid
US5045304A (en) * 1988-08-31 1991-09-03 Wayne State University Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same
US5411863A (en) * 1988-12-28 1995-05-02 S. Miltenyi Methods and materials for improved high gradient magnetic separation of biological materials
US5160726A (en) * 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US5268165A (en) * 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
US5328681A (en) * 1991-01-19 1994-07-12 Meito Sangyo Kabushiki Kaisha Composition comprising magnetic metal oxide ultrafine particles and derivatized polysaccharides
US5424419A (en) * 1991-06-11 1995-06-13 Meito Sangyo Kabushiki Kaisha Oxidized complex comprising water-soluble carboxypolysaccharide and magnetic iron oxide
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
US5766572A (en) * 1992-08-05 1998-06-16 Meito Sangyo Kabushiki Kaisha Water-soluble carboxypolysaccharide-magnetic iron oxide complex having a small particle diameter
US5916539A (en) * 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US6048515A (en) * 1994-08-04 2000-04-11 Institut Fur Diagnostikforschung Gmbh Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US6207134B1 (en) * 1994-09-27 2001-03-27 Nycomed Imaging As Ultrafine lightly coated superparamagnetic particles for MRI
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
US6517813B1 (en) * 1996-08-05 2003-02-11 Schering Ag Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026823A1 (en) * 2004-09-09 2006-03-16 Bell, Glenda, Fay Separation of plastic and elastomers for food and pharmaceutical products
US20070205529A1 (en) * 2004-09-09 2007-09-06 May Donald B Separation of plastic and elastomers for food and pharmaceutical products
US20090299172A1 (en) * 2006-06-06 2009-12-03 Guerbet Water Diffusion imaging and Uspio
CN102178986A (en) * 2011-04-13 2011-09-14 李明 Blood extracorporeal circulation magnetic sterilizing device

Also Published As

Publication number Publication date
WO1998005430A1 (en) 1998-02-12
CA2262685A1 (en) 1998-02-12
KR100502881B1 (en) 2005-07-25
CN1230136A (en) 1999-09-29
CA2262685C (en) 2008-09-23
AU3941597A (en) 1998-02-25
DE59706019D1 (en) 2002-02-21
KR20000029821A (en) 2000-05-25
IL128057A0 (en) 1999-11-30
ATE211950T1 (en) 2002-02-15
DK0915738T3 (en) 2002-05-06
IL128057A (en) 2001-08-26
PT915738E (en) 2002-07-31
NO990523D0 (en) 1999-02-04
US6517813B1 (en) 2003-02-11
HUP0001608A3 (en) 2001-01-29
EP0915738A1 (en) 1999-05-19
NO318377B1 (en) 2005-03-14
AR008817A1 (en) 2000-02-23
EP0915738B1 (en) 2002-01-16
NZ333962A (en) 2000-07-28
JP2000516131A (en) 2000-12-05
CN1151846C (en) 2004-06-02
ZA976967B (en) 1998-02-19
NO990523L (en) 1999-03-30
ES2171985T3 (en) 2002-09-16
DE29713847U1 (en) 1997-12-18
HUP0001608A1 (en) 2000-09-28
AU727764B2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
US6517813B1 (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device
Laurent et al. Iron oxide based MR contrast agents: from chemistry to cell labeling
Tombácz et al. Magnetic iron oxide nanoparticles: Recent trends in design and synthesis of magnetoresponsive nanosystems
Ruuge et al. Magnetic fluids as drug carriers: Targeted transport of drugs by a magnetic field
US6616623B1 (en) System for correction of a biological fluid
Charles The preparation of magnetic fluids
WO2008080047A2 (en) Magnetic separation of fine particles from compositions
Vedernikova Magnetic nanoparticles: Advantages of using, methods for preparation, characterization, application in pharmacy
Kaminski et al. Detoxification of blood using injectable magnetic nanospheres: A conceptual technology description
Gómez-Pastora et al. The reverse of controlled release: Controlled sequestration of species and biotoxins into nanoparticles (NPs)
US8765922B2 (en) Device and method for separation of Neél- and brown-magnetic particles
WO1989003675A1 (en) Superparamagnetic particles, a way of producing said particles and their use
Stamopoulos et al. Bare and protein-conjugated Fe3O4 ferromagnetic nanoparticles for utilization in magnetically assisted hemodialysis: biocompatibility with human blood cells
Ali et al. Size and shape control synthesis of iron oxide–based nanoparticles: current status and future possibility
A Silva et al. Magnetic carriers: a promising device for targeting drugs into the human body
CN108289990A (en) Magnetic filtration device device and method
MXPA99001229A (en) Process and device for separating magnetic materials from pharmaceutical compositions, their starting or intermediate products and agents produced by means of this device
York et al. The effects of particle shape and size on T 2 relaxation in magnetic resonance imaging
Podoynitsyn et al. High-gradient magnetic separation of nanoparticles with ferromagnetic track-etched membrane
Rarokar et al. Magnetic nanosystem a tool for targeted delivery and diagnostic application: Current challenges and recent advancement
Hastak et al. Magnetic Iron oxide nanoparticles for biomedical applications
Mayeen et al. Surface Chemistry and Properties of Magnetic Nanoparticles
Swain et al. Magnetically modulated drug delivery systems
Owings High Gradient Magnetic Separation of nanoscale magnetite.
Bossmann et al. Biosensing and Cancer Treatment with Magnetic Nanoparticles

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334

Effective date: 20061229

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334

Effective date: 20061229

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION